Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2025)

Maravai Lifesciences Holdings has reported FCF Margin over the past 6 years, most recently at 30.89% for Q4 2025.

  • Quarterly results put FCF Margin at 30.89% for Q4 2025, up 534.0% from a year ago — trailing twelve months through Dec 2025 was 32.97% (down 2441.0% YoY), and the annual figure for FY2025 was 32.97%, down 2441.0%.
  • FCF Margin for Q4 2025 was 30.89% at Maravai Lifesciences Holdings, up from 58.76% in the prior quarter.
  • Over the last five years, FCF Margin for MRVI hit a ceiling of 97.7% in Q1 2023 and a floor of 72.92% in Q4 2023.
  • Median FCF Margin over the past 5 years was 21.7% (2021), compared with a mean of 16.1%.
  • Biggest five-year swings in FCF Margin: skyrocketed 6190bps in 2021 and later crashed -12592bps in 2023.
  • Maravai Lifesciences Holdings' FCF Margin stood at 25.15% in 2021, then surged by 111bps to 53.01% in 2022, then plummeted by -238bps to 72.92% in 2023, then skyrocketed by 50bps to 36.22% in 2024, then rose by 15bps to 30.89% in 2025.
  • The last three reported values for FCF Margin were 30.89% (Q4 2025), 58.76% (Q3 2025), and 14.25% (Q2 2025) per Business Quant data.